title: Erythropoietin therapy in patients with chronic renal failure.
abstract: Symptomatic anemia is a common complication of chronic renal failure. Treatment is now possible with the availability of recombinant human erythropoietin (epoetin alfa). Previous experimental studies have suggested that correcting the anemia of chronic renal failure may be harmful in that renal failure may be accelerated. Although experience with this drug has been primarily restricted to its use in patients with end-stage renal disease, several recent trials have been reported in patients with varying degrees of chronic renal failure. We review these studies with particular reference to the progression of renal failure and the drug's reported side effects. We conclude that the use of epoetin is beneficial and well tolerated and that there is no compelling evidence for the acceleration of renal failure associated with its use in patients.
authors.affiliation: Division of Nephrology, Mercy Hospital, Pittsburgh, Pennsylvania.
authors.forename: A J
authors.initials: AJ
authors.lastname: Pinevich
authors.forename: J
authors.initials: J
authors.lastname: Petersen
mesh_terms: D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D000818:Animals; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use*; D006400:Hematocrit; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007676:Kidney Failure, Chronic / Q000150:complications*; D051381:Rats; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin